Formestane

Formestane

Systematic (IUPAC) name
(8R,9S,10R,13S,14S)-4-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione
Clinical data
Trade names	Lentaron
AHFS/Drugs.com	International Drug Names
Identifiers
CAS Number	566-48-3
ATC code	L02BG02 (WHO)
PubChem	CID 11273
ChemSpider	10799
UNII	PUB9T8T355
KEGG	D07260
ChEBI	CHEBI:75172
ChEMBL	CHEMBL132530
Synonyms	4-hydroxyandrost-4-ene-3,17-dione
Chemical data
Formula	C19H26O3
Molar mass	302.408 g/mol
SMILES O=C4C(/O)=C3/CC[C@@H]2[C@H](CC[C@@]1(C(=O)CC[C@H]12)C)[C@@]3(C)CC4
InChI InChI=1S/C19H26O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,22H,3-10H2,1-2H3/t11-,12-,13-,18+,19-/m0/s1 Key:OSVMTWJCGUFAOD-KZQROQTASA-N
(what is this?)  (verify)

Formestane (trade name Lentaron) is a type I, steroidal, selective aromatase inhibitor.^[1] It is used in the treatment of estrogen receptor-positive breast cancer in postmenopausal women. The drug is not active orally, and is instead available only as an intramuscular depot injection. Because of this, it is no longer popular as many orally active aromatase inhibitors have been identified and introduced. Formestane is an analogue of androstenedione.

Formestane is often used to suppress the production of estrogens from anabolic steroids or prohormones. It also acts as a prohormone to 4-hydroxytestosterone, an active steroid which displays weak androgenic activity in addition to acting as a weak aromatase inhibitor.

References

1. Pérez Carrión R, Alberola Candel V, Calabresi F; et al. (1994). "Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer". Ann. Oncol. 5 Suppl 7: S19–24. PMID 7873457.